Disruptive Clinical Development: Are you driving the change needed to pioneer personalized medicine?

Seismic shifts in clinical development are required to realize the true promise of personalized medicine. Although skeptics wonder when this change will happen, the list of approved targeted therapeutics is growing every year - Gleevec®, Herceptin®, Iressa®, Rituxan®, and Tarceva® are just the tip of the iceberg. Personalized medicine is steadily emerging as the new healthcare paradigm. As the industry searches for ways to embrace personalized medicine, it is being challenged to form creative partnerships and develop new business structures that will support its clinical development.

At Partnerships in Clinical Trials 2012, you'll hear preeminent industry thought leaders tackle the obstacles of personalized medicine and discuss how traditional clinical development needs to change to support the move towards tailored therapeutics. Never before has a group of such experts including a scientific leader, a pharmaceutical industry guru, a biotech innovator and a payor come together to remove the barriers for progress and push clinical development forward.

• - J. Craig Venter, Founder, Chairman, and President, J. Craig Venter Institute and Founder & CEO, Synthetic Genomics Inc.
• - Bernard Munos, Chief Apostle, Breakthrough Innovation, Innothink Center for Research in Biomedical Innovation
• - Matthew Emmens, Chairman & CEO, Vertex Pharmaceuticals
• - Felix Frueh, PhD, President, Medco Research Institute, Medco Health Solutions, Inc.

Download the brochure here to find out more about these presentations and the rest of the new Partnerships Experience.

As a reader of the Partnerships in clinical trials blog, you receive an exclusive discount of 15% off of the standard price when you register to join us this March 4-7, 2012 in Orlando, FL. Simply use priority code XP1700Blog when you register to claim this discount. Have any questions about the event? Feel free to contact Jennifer Pereira.